EXPRESSION OF MATRIX METALLOPROTEINASE-3 STAGE-I AND STAGE-II SQUAMOUS-CELL CARCINOMA OF THE ORAL CAVITY

被引:50
作者
KUSUKAWA, J [1 ]
SASAGURI, Y [1 ]
MORIMATSU, M [1 ]
KAMEYAMA, T [1 ]
机构
[1] KURUME UNIV,SCH MED,DEPT PATHOL,KURUME,FUKUOKA 830,JAPAN
关键词
D O I
10.1016/0278-2391(95)90065-9
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Purpose: The object of this study was to evaluate the significance of matrix metalloproteinase-3 (MMP-3) in tumor invasion and metastasis of early squamous cell carcinoma (SCC) of the oral cavity. Materials and Methods, Surgical specimens from 65 patients with stage I and II SCC of the oral cavity were the subjects of this study. Tissue specimens were fixed in formalin and embedded in paraffin, and the sections were stained with monospecific antibodies against human MMP-3 by the avidin-biotin-peroxidase complex method. Results: Of the 65 patients, 30 (46.2%) tested positive for MMP-3, Immunoreactivity revealed the expression of MMP-3 to be in the small cancer nests in the advancing front of invasion, but not in normal oral epithelium. MMP-3 expression was positively correlated with tumor size, depth of tumor invasion, diffuse invasive mode, and the high incidence of lymph node metastasis. Conclusion: MMP-3-containing tumors will invade adjacent normal tissues more aggressively, including lymphatic and blood vessels, Therefore, the examination of MMP-3 expression in biopsy specimens should provide information useful in predicting the malignant potential of early SCC of the oral cavity.
引用
收藏
页码:530 / 534
页数:5
相关论文
共 30 条
[1]  
AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO
[2]  
2-L
[3]  
BROWN B, 1989, CANCER, V64, P1195, DOI 10.1002/1097-0142(19890915)64:6<1195::AID-CNCR2820640606>3.0.CO
[4]  
2-7
[5]   MALIGNANCY GRADING OF THE DEEP INVASIVE MARGINS OF ORAL SQUAMOUS-CELL CARCINOMAS HAS HIGH PROGNOSTIC VALUE [J].
BRYNE, M ;
KOPPANG, HS ;
LILLENG, R ;
KJAERHEIM, A .
JOURNAL OF PATHOLOGY, 1992, 166 (04) :375-381
[6]  
DREYFUSS AI, 1992, CANCER-AM CANCER SOC, V70, P2499, DOI 10.1002/1097-0142(19921115)70:10<2499::AID-CNCR2820701018>3.0.CO
[7]  
2-#
[8]  
Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T
[9]  
GRANDIS JR, 1992, OTOLARYNG CLIN N AM, V25, P1105
[10]  
GRAY ST, 1992, AM J PATHOL, V141, P301